Tyra Biosciences logo
Tyra Biosciences
TYRA | NASDAQ
Chart Builder DCF Calculator
$19.74
-$0.29 (-1.42%)
At close: Nov 16, 2026, 4:00 PM ET
$19.74
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Tyra Biosciences Company Profile

Company profile explained

Company Profile

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Key Executives

Name Position
Todd Harris Co-Founder, CEO, President & Director
Alan Fuhrman Chief Financial Officer
Bhavesh Ashar Chief Operating Officer
Robert L. Hudkins Chief Technology Officer
Ali D. Fawaz General Counsel & Secretary
Daniel Bensen Co-Founder & Chief Discovery Officer
Douglas Warner Chief Medical Officer
Julia Rueb VP of Finance & Principal Accounting Officer
Ronald V. Swanson Chief Scientific Officer
Sarah Honig Senior Vice President of Corporate Development & Strategy

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 21, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 SC 13D/A [Amend] Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 15, 2026 8-K Current Report
Sep 15, 2026 424B5 Filing
View All SEC Filings ➞
Tyra Biosciences
Tyra Biosciences logo
Country United States
IPO Date Sep 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 87
CEO Todd Harris

Contact Details

2656 State Street Carlsbad, California 92008 United States

Stock Details

Ticker Symbol TYRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001863127
CUSIP Number 90240B106
ISIN Number US90240B1061
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.